Atypical Fractures of the Femur Associated with Chronic Treatment with Bisphosphonates Grzegorz Fijewski, Bartłomiej Szostakowski, Radosław Górski, Piotr Modzelewski, Piotr Dudek, Paweł Małdyk Ortop Traumatol Rehabil 2016; 18(3):239-249 ICID: 1212868
Article type: Original article
IC™ Value: 3.00
Abstract provided by Publisher
Background. The problem of atypical fractures, such as subtrochanteric or diaphyseal femoral fractures, associated with long-term treatment with bisphosphonates (BPs) has recently been given increasingly more attention. These fractures develop as stress fractures and are characterised by diaphyseal cortical thickening and a transverse or slightly oblique fracture line. The use of bisphosphonates has been documented to reduce the risk of osteoporotic fractures. However, an increasing number of papers verify the safety and benefits of the administration of these drugs over more than 3-5 years. Material and methods. This paper presents 13 cases of atypical femoral fractures in 11 patients of the Department of Orthopaedics and Traumatology of the Musculoskeletal System of the Warsaw Medical University. Results. All patients had been taking BPs for a mean period of over 13 years (between 2 and 25 years) before the fracture. Conclusions. 1. The authors stress that these fractures differ from “classic” osteoporotic fractures. 2. The authors indicate surgical treatment of these fractures (even incomplete ones) as a method of choice. 3. The authors suggest that the need for further BP therapy should be assessed after 3-5 years of treatment.
DOI 10.5604/15093492.1212868 PMID 28157080 - click here to show this article in PubMed